Study of Sensitization of Non-M3 AML Blasts to ATRA by Epigenetic Treatment With Tranylcypromine (TCP)
Status:
Recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
The objective of the phase I part of the trial is the determination of the maximum tolerated
dose (MTD) of TCP (Tranylcypromine) in combination with fixed-dose ATRA (all-trans-retinoic
acid) and with fixed-dose AraC (Cytarabine) and to derive the recommended phase II dose
(RP2D) in patients with non-APL AML or MDS for whom no standard treatment is available or who
failed azanucleoside treatment.
The objective of the phase II part of the trial is a first evaluation of the efficacy of TCP
at the RP2D in combination with fixed-dose ATRA and with fixed-dose AraC as basis for further
investigations of TCP